Management of fungal infections in lung transplant recipients

Pappas PG et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11. Doligalski CT et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant. 2014;14(6):1328–33. These documents incorporate information from database, large clinical studies, and guidelines in fungal infections in solid organ transplant recipients in general and lung transplant in particular; describing both diagnostic and therapeutic issues in this type of population. Iversen M et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26(12):879–86. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol. 2005;43 Suppl 1:S267–70. Luong ML et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation. 2014;97(3):351–7. These documents incorporate information from database, large clinical studies, and guidelines in fungal infections in solid organ transplant recipients in general and lung transplant in particular; describing both diagnostic and therapeutic issues in this type of population. Singh N et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36(1):46–52. Mehrad B et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest. 2001;119(1):169–75. Cahill BC et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112(5):1160–4. Nunley DR et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998;114(5):1321–9. Helmi M et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest. 2003;123(3):800–8. Weigt SS et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9(8):1903–11. Hsu JL et al. Aspergillus fumigatus invasion increases with progressive airway ischemia. PLoS ONE. 2013;8(10):e77136. Husni RN et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998;26(3):753–5. Goldfarb NS et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation. 2001;71(2):242–6. Husain S et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6(12):3008–16. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22(3):258–66. Greene RE et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44(3):373–9. Park SY et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl Infect Dis. 2010;12(4):309–15. Gazzoni FF et al. High-resolution computed tomographic findings of Aspergillus infection in lung transplant patients. Eur J Radiol. 2014;83(1):79–83. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005;18(1):44–69. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417–27. Husain S et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant. 2004;4(5):796–802. Guo YL et al. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest. 2010;138(4):817–24. Pasqualotto AC et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation. 2010;90(3):306–11. Luong ML et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis. 2011;52(10):1218–26. Clancy CJ et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007;45(6):1759–65. Mikulska M et al. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012;67(7):1746–8. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis. 2005;5(10):609–22. White PL et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol. 2011;49(11):3842–8. Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60. Herbrecht R et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15. Han K et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother. 2010;54(10):4424–31. Pascual A et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381–90. Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11. Mitsani D et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56(5):2371–7. These documents incorporate information from database, large clinical studies, and guidelines in fungal infections in solid organ transplant recipients in general and lung transplant in particular; describing both diagnostic and therapeutic issues in this type of population. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol. 1998;36(10):2950–6. Pfaller MA et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46(4):1032–7. Walsh TJ et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12. Groetzner J et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008;27(1):1–6. Hiemenz JW et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis. 2010;29(11):1387–94. Neoh CF et al. Antifungal prophylaxis in lung transplantation—a world-wide survey. Am J Transplant. 2011;11(2):361–6. Bhaskaran A, Mumtaz K, Husain S. Anti-aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep. 2013;15(6):514–25. These documents incorporate information from database, large clinical studies, and guidelines in fungal infections in solid organ transplant recipients in general and lung transplant in particular; describing both diagnostic and therapeutic issues in this type of population. Baum GL. The significance of Candida albicans in human sputum. N Engl J Med. 1960;263:70–3. Rose HD, Sheth NK. Pulmonary candidiasis. A clinical and pathological correlation. Arch Intern Med. 1978;138(6):964–5. Haron E et al. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore). 1993;72(3):137–42. Neofytos D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–9. Schaenman JM et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis. 2009;11(2):112–21. Nunley DR et al. Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation. Chest. 2002;122(4):1185–91. Kanj SS et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore). 1996;75(3):142–56. Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35. Lockhart SR et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10. Sahi H et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant. 2007;26(4):350–6. Cimon B et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000;19(1):53–6. Morio F et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol. 2010;48(5):1978–82. Cortez KJ et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21(1):157–97. Cooley L et al. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis. 2007;13(8):1170–7. Berenguer J et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore). 1997;76(4):256–65. Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J Chemother. 2003;15 Suppl 2:16–27. Husain S et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40(1):89–99. Troke P et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743–50. Meletiadis J et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46(1):62–8. Cuenca-Estrella M, Rodriguez-Tudela JL. Present status of the detection of antifungal resistance: the perspective from both sides of the ocean. Clin Microbiol Infect. 2001;7 Suppl 2:46–53. Steinbach WJ et al. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41(8):3981–5. Bhat SV et al. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis. 2007;39(1):87–90. Musk M et al. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant. 2006;25(10):1268–72. Almyroudis NG et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6(10):2365–74. Sun HY et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009;9(9):2166–71. Manchikalapati P et al. Gastrointestinal zygomycosis complicating heart and lung transplantation in a patient with Eisenmenger’s syndrome. Dig Dis Sci. 2005;50(6):1181–3. McGuire FR, Grinnan DC, Robbins M. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J Heart Lung Transplant. 2007;26(8):857–61. Page AV et al. Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature. Transpl Infect Dis. 2008;10(6):419–25. Wingard JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood. 2012;120(9):1791–800. Cornely OA et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20 Suppl 3:5–26. These documents incorporate information from database, large clinical studies, and guidelines in fungal infections in solid organ transplant recipients in general and lung transplant in particular; describing both diagnostic and therapeutic issues in this type of population. Ibrahim AS et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–8. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7(4):479–504. O’Donnell K et al. Genetic diversity of human pathogenic members of the Fusarium oxysporum complex inferred from multilocus DNA sequence data and amplified fragment length polymorphism analyses: evidence for the recent dispersion of a geographically widespread clonal lineage and nosocomial origin. J Clin Microbiol. 2004;42(11):5109–20. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704. Carneiro HA et al. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore). 2011;90(1):69–80. Healy M et al. Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates. J Clin Microbiol. 2005;43(10):5278–80. Liu K et al. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109(1):45–54. Tortorano AM et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20 Suppl 3:27–46. These documents provides an important information about selected diagnostic and therapeutic methods in lung transplant recipients but in a smaller scale. Lupinetti FM, Giller RH, Trigg ME. Operative treatment of Fusarium fungal infection of the lung. Ann Thorac Surg. 1990;49(6):991–2. Baddley JW, Forrest GN. Cryptococcosis in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:242–9. These documents incorporate information from database, large clinical studies, and guidelines in fungal infections in solid organ transplant recipients in general and lung transplant in particular; describing both diagnostic and therapeutic issues in this type of population. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001;7(3):375–81. Kontoyiannis DP et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100. Sun HY et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis. 2010;51(9):1062–9. Singh N et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007;195(5):756–64. Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant. 2002;2(7):575–80. Antinori S et al. The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis. J Clin Microbiol. 2005;43(11):5828–9. Singh N et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis. 2008;46(2):e12–8. Lortholary O et al. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2004;25(2):145–57. Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322. Singh N et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005;40(12):1756–61. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007;7(6):395–401. Sun HY et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis. 2015;60(1):36–44. These documents provides an important information about selected diagnostic and therapeutic methods in lung transplant recipients but in a smaller scale.